Class effect beyond glucose: Implications of the LEGEND‐T2DM findings for cardiovascular outcomes
Yuexing Liu, Weiping Jia · 2026
Read Class effect beyond glucose: Implications of the LEGEND‐T2DM findings for cardiovascular outcomes by Yuexing Liu, Weiping Jia (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13570371.txt.
Description
Yuexing Liu and Weiping Jia comment, in a paper published in 2026, on a large study of diabetes drugs and heart outcomes. Modern diabetes care weighs heart and kidney risk alongside blood sugar. Two newer drug classes cut heart events in trials, but they had never been compared directly with older, cheaper classes in daily practice.
The study they discuss, LEGEND-T2DM, mined claim databases to compare second-line drugs for people with type 2 diabetes and heart disease already on metformin. It offered the first broad real-world contrast of newer agents with sulfonylureas and DPP-4 inhibitors, and of the two newer classes with each other. Liu and Jia argue the results support treating the heart benefits as shared across each class, not tied to one brand. Prescribing can thus lean on patient fit.
Catalog record
| CREATOR | Yuexing Liu, Weiping Jia |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 12 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |